

CANbridge Pharmaceuticals

2023 Interim Result Presentation

Aug 2023



Disclaimer

THIS DOCUMENT OR THE CONTAINED **INFORMATION** HEREIN IS NOT INTENDED TO AND DOES NOT CONSTITUTE ANY OFFER OR INVITATION. SOLICITATION. COMMITMENT OR ADVERTISEMENT OF ANY FOR SUBSCRIPTION. OFFER PURHCASE OR SALE OF ANY SECURITIES, NOR SHALL ANY OF THIS DOC UM ENT PART THE BASIS OF OR BE FORM RELIED ON IN CONNECTION WITH ANY CONTRACT OR COMMITMENT WHATSOEVER.

This document contains strictly confidential and proprietary information in relation to CANbridge Pharmaceuticals Inc. (the "Company") and is only being made available on a confidential basis for the exclusive use of the person to whom it is addressed (the "Recipient") and may not be reproduced or transmitted to any other person. The information contained in this document has not been independently verified by the Company and its directors, management, employees, agents, affiliated entities or persons, advisers or representatives (collectively, the "Representatives"). By accepting this document, you agree that you and your representatives shall not cite this document, in whole or in part, at any time, in any manner or for any purpose without the prior written consent of the Company. If you are not the information contained in this document, not person accuracy of the information contained in this document, nor the reasonableness of any assumptions herein, and no party shall be entitled to rely on the fairness, reliability, completeness or accuracy of the information in connection with any proposed investment in the Company ("Proposed Investment"), and the reasonableness of any assumptions herein is shall not be updated to reflect any material development after the date of this document. Neither the Company on the representatives shall have any liability for any loss in connection with this document in this document. The information contained herein is showever arising in connection with this document. The Company and the information that may be required by or otherwise important to the Recipient and by our representatives and the restored in this document. In whole or in part, at any time, in any manner or for any purpose without the prior written consent of the Company. If you are not the information contained in this document, nor the reasonableness


This document may contain forward-looking statements. Such forward-looking statements are based on a number of assumptions in connection with the Company's operation and future development plan, market (financial and other aspects) conditions, industry and regulatory trends, and growth prospect. The validity of such assumptions are affected by a number of factors, both identified and unknown, and includes factors beyond the Company's control, and such factors may cause material deviations between the Company's actual performance to that expressed or implied in such forward-looking statement. You are cautioned not to place undue reliance on these forward-looking statements, as these statements are subject to risks both identified and unknown, involve inherent uncertainties and speaks only as of the date they are made. Neither the Company nor the Representatives shall be responsible updating the forward-looking statements in accordance with events or circumstances that occur after the date of this document. This document has been prepared solely for information purposes and does not constitute a recommendation regarding any offer for subscription for the securities of the Company and does not constitute and should not be considered as any form of financial or investment opinion or recommendation by the Company or the Representatives. The shares of the Company have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or the securities laws of any state of the United States or any other jurisdiction outside Hong Kong. The shares of the Company may not be offered or sold within the United States, or to or for the account or benefit of U.S. persons (as such term is defined in Regulation S under the Securities Act), absent registration under the Securities Act or except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state or local securities laws. Any public offering in the United States must be conducted with a prospectus that shall contain detailed information about the company and its management, as well as financial statements. Such prospectus may be obtained from the company or the selling security holders. This document does not constitute a prospectus as defined by the Securities Act. The Company does not intend to conduct a public off ering of securities in the United States, register or apply for registration of any portion of any offering under the Securities Act. Nothing in this document constitutes an offer of securities for sale or solicitation of an offer to buy or subscribe for securities in the United States or any jurisdiction where it is unlawful to do so. In Hong Kong, the shares of the Company may not be offered to the public unless a prospectus in connection with such sale or offer for subscription has been duly registered with the Hong Kong Companies Registry in accordance with the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap 32 of the laws of Hong Kong) (the "Companies Ordinance"). An prospectus which has not been so registered may not be distributed, issued or circulated, but may be distributed to professional investors in accordance with the Securities and Futures Ordinance (Cap 571 of the laws of Hong Kong) (the "Securities and Futures Ordinance"). This document does not constitute a prospectus as defined by the Companies Ordinance. This document contains no information or material which may result in it being deemed (1) to be a prospectus within the meaning of section 2(1) of the Companies Ordinance, or an advertisement in relation to a prospectus or proposed prospectus or extract from or abridaed version of a prospectus within the meaning of section 38B of the Companies Ordinance or an advertisement, invitation or document containing an advertisement or invitation falling within the meaning of section 103 of the Securities and Futures Ordinance, or (2) in Hong Kong to have effected an offer to the public without compliance with the laws of Hong Kong or being able to invoke any exemption available under the laws of Hong Kong, and is subject to material change without notice. Neither this document nor any part or copy of it may be taken or transmitted into or distributed in or into, directly, the U.S. (including the territory and dependency of the U.S.). Any failure to comply with these restrictions may constitute a violation of U.S. securities laws. The distribution of this document in certain jurisdictions may be restricted by law, and persons into whose possession this document come should inform themselves about, and observe, any such restrictions. This document is not directed to, or intended for distribution to or use by, any person or entity that is a citizen or resident in any jurisdiction where such distribution or use would be contrary to law or regulation or which would require any registration or licensing within such jurisdiction. Nothing in this document should be construed as regulatory, valuation, legal, tax, accounting or investment advice and it does not constitute a recommendation, solicitation, offer or commitment to purchase, sell or underwrite any securities from you, to you, or on your behalf, or to extend any credit or provide any insurance to you or to enter into any transaction. Unless otherwise agreed in writing, any third party from whom you receive this document is not acting as your financial adviser or fiduciary. Before you enter into any transaction, you should ensure that you fully understand the potential risks and rewards of that transaction and you should consult with such advisers as you deem necessary to assist you in making these determinations, including, but not limited to, your accountants, investment advisers and legal and/or tax experts.

By accepting delivery of or accessing this document, you are deemed to represent irrevocably and unconditionally to the Company and its agents, affiliated entities or persons, advisers and representatives that you and any customers you represent are "qualified institutional buy ers" as defined in Rule 144A under the Securities Act, persons outside the United States for the purpose of Regulation S under the Securities Act, or professional investor as defined in the Securities and Futures Ordinance. The information contained herein is directed solely at such investors. Any investment or investment activity to which the information in this document relates is only available to such investors. Other persons should not access, rely on or act upon this document or any of its contents. All enquiries or requests for additional information in connection with this document should be contacted directly under any circumstances in connection with this document may relation of negotiations in relation to the Proposed Investment, if any. If you do not accept the forgoing conditions or any confirmations and representations contained herein, please immediately return this document to the Company."



Our Vision









To be a Global Biopharmaceutical Company Delivering Lifechanging Therapies to Patients Built Upon a Foundation in China



Key Investment Highlights








CANbridge Today

Well-positioned to Deliver Multiple Commercial and Development Milestones in Rare Diseases



Well-established Commercialization Infrastructure

Launched Products



Hunterase

- Hunterase has entered into 109 cities' commercial insurance program ("Huiminbao") as of June 30, 2023
- 72% of Hunterase treated patients are covered by commercial insurance
- Expected NRDL inclusion in 2024 and 10 newly expanded target cities with commercial insurance coverage



Livmarli

- Expected NRDL inclusion in 2024 and 4 newly expanded target cities with commercial insurance coverage
- Launch of Livmarli-ALGS in China in Q1 2024
- Dedicated sales team of 12 professionals support early launch to cover 98 hospitals and 300 healthcare physicians

Expect 5 new launches in 5 years, including CAN103, CAN108-PFIC, CAN108-BA, CAN106 and CAN008

Established Commercial Infrastructure in Greater China



20+ years of experience in leading emerging market teams, establishing marketing and commercial operations, and regional country management
 Deep experience in successful launches of multiple products globally including Eloctate, Alprolix, Thy rogen, Cerezy me, etc.
 Synageva Ultragenty



Responsible for the commercial operations in Mainland China
 17+ years of commercial experience in v arious companies including BMS, AbbVie and GSK, where she contributed in launching numerous key oncology, hematology, hepatology and respiratory products

🖑 Bristol Myers Squibb

/ GM of HK and Macau Obbvie




Commercialization team of 40+ experienced professionals

Broad Geographical Coverage in Mainland China						
	Before NRDL	After NRDL				
Covered Province #	22	30				
Covered City #	~50	~180				
Covered Hospital #	~300	~1,100				
Covered KOL #	~1,500	~5,500				
Covered Population # Mn	~550	~1,130				

Established commercial infrastructure in HK and Taiwan to drive robust sales



Access to GMP Manufacturing Capability for Multiple Modalities



Our Comprehensive and Diversified Pipeline

CANbridge holds global rights to 8 out of 14 assets, spanning biologics, small molecules, and gene therapy, targeting most prevalent rare diseases and oncology indications, with proven mechanisms and significant market potential

		Candidate	Mechanism	Discovery	IND-enabling	Ph 1	Ph 2/3	NDA	Marketed	Dev Strategy	Partner	Commercial Rights
Rare Onc.	ğ	CAN008 (Asunercept)	CD95-Fc fusion protein	Glioblastoma Multiforn	ne						apogenix	Greater China
	ð	Hunterase® (ldursulfase beta)	ERT IDS	Hunter Syndrome (Mu	ucopolysaccharidosis	Type II)				In China for China	🔶 GC Pharma	Greater China
				Alagille Syndrome								
	Ĩ	Livmarli® (CAN 108)	IBAT inhibitor	Progressive Familial Ir	ntrahepatic Cholestas	is					: mirum	Greater China
		(0/11/100)		Biliary Atresia								
	¥	CAN 106	Anti-C5 mAb	Paroxysmal Nocturn	nal Hemoglobinuria						Wuxi Biologies //Privus	Global
	¥	CAN 103	ERT GBA	Gaucher Disease						In China	WuXi Biologics	Global
Rare Disease	ğ	CAN 107	Anti-FGF23 mAb	XLH						for Global	WuXi Biologics /Privus	Global
	¥	CAN 104	ERT GLA	Fabry Disease						In China	WuXi Biologics	Global
	ð	CAN 105	Anti-Factor IXa/X bsAb	Hemophilia A						In China for China	WuXi Biologics Global Solution Provider	Greater China
	Ą.	CAN 201	AAV sL65 GLA	Fabry Disease								Global
	¥.	CAN 202	AAV sL65 GAA	Pompe Disease						Global for Global		Global
	¥.	CAN 203	AAV SMN1	SMA						Clobal	UMass Chan MEDICAL SCHOOL	Global
	Ą.	Undisclosed	AAV	DMD							UW Medicine UW SCHOOL OF MEDICINE	Global
Other	Ö	Caphosol™	Calcium phosphate rinse	Oral Mucositis							EUSAPharma	China
Onc.	Ę,	Nerlynx®(Neratinib)	Tyrosine kinase inhibitor	HER2+ Breast Cance	r						S Pierre Fabre	Hong Kong, Taiwan, Macau
		Clinical trials perfor license partner	rmed by 🛛 🖉 Biologic		Gene 🛱 Medi Therapy Devi					Ċ	САПР	ridge

Pipeline Targets Diseases with \$15 Billion Potential


Commercial Rights	Pipeline	Indications	Preva	alence		Global Sales	
	Hunterase®	MPS II	8 🚯	ßk	\$	>500 M	 \$ 2022 Global Sales (US\$) \$ 2022 Global / China Prevalence
		Alagille Syndrome	3 1	0k	\$	75 M	
China	Livmarli (CAN108)	PFIC	🍪 5k		\$	>25 M	
	(0/ 11/ 00)	Biliary Atresia	6 .	😵 6.5k* 💲 NA	NA	Abbreviations: GBM – Glioblastoma	
	CAN008	GBM	6 5	5k	\$	NA	Multiforme; MPS II – Mucopolysaccharidosis type II; ALGS – Alagille Syndrome; PFIC –
		PNH	🧐 23k	😚 124k			Progressive Familial Intrahepatic Cholestasis; PNH – Paroxysmal nocturnal
	CAN106	aHUS	🧐 10k	😚 32k	S	>5 B Uremi	hemoglobinuria; aHUS – Atypical Hemolytic
		gMG	🤣 234k	😚 1,290k	•		Uremic Syndrome; gMG – Generalized Myasthenia Gravis; NMOSD – Neuromyelitis
		NMOSD	🚱 55k	😚 171k			Optica Spectrum Disorders; XLH – X-linked
	CAN 203	SMA	🤣 14k	😚 78k	\$	1.4 B	hypophosphatemia; PD – Pompe Disease. Source: Frost & Sullivan and CANbridge
Global	CAN103	Gaucher Disease	3 7	′8k	\$	>1.5 B	Analysis, NCBI research, Endocrine Journal
	CAN104 CAN201	Fabry Disease	(1,7	′89k	\$	~2 B	research, World Federation of Hemophilia research
	CAN202	Pompe Disease	😚 17	Ök	\$	>1 B	Notes: CAN008 currently has no
	CAN107	XLH	贪 11	7k	\$	~1 B	commercialized comparable product.
	CAN105	Hemophilia A	😚 34	l0k	\$	~4 B	

Note: targeted patient pool



Past and Upcoming Milestones

Two products planned for NRDL negotiation in 2023 and Multiple NDA filings expected by 4Q2024



1 : IDMC, Independent Data Monitoring Committee,

2 : ASGCT, American Society of Gene and Cell Therapy Annual Meeting



Pipeline Portfolio Update





Livmarli[®] (CAN108):

Near-term Launch in Rare Cholestatic Liver Diseases in China

Livmarli – IBAT Inhibitor for Rare Cholestatic Liver Diseases

A novel, oral, minimally-absorbed agent designed to selectively inhibit IBAT in the ileum and treat rare cholestatic liver diseases, including ALGS, PFIC and BA

Recent Highlights

- Received China NMPA marketing approval for ALGS in 1H 2023
- Filed Hong Kong/Taiwan FDA for ALGS, with estimated approval by the end of 2023
- Mirum realized \$75.1 million in LIVMARLI (maralixibat) net product sales in the first full fiscal year of its U.S. launch
- Mirum dosed first patient in Phase 2 BA China study and reported positive topline Phase 3 PFIC data and label expansion for ALGS to include infants of 3 months+

Mechanism of Action


- 1. IBAT is primarily responsible for recycling bile acids from the intestine ileum back to the liver
- 2. Elevated bile acids damage the liver and lead to cholestatic liver disease
- Livmarli is designed to inhibit IBAT in the ileum and result in more bile acids being excreted in the feces, leading to lower levels of bile acids systemically, thereby reducing bile acid mediated effects and liver damage

Disease Overview

- Alagille Syndrome (ALGS): a rare genetic disorder that can affect multiple organ systems of the body, including the liver, heart, skeleton, eyes and kidneys. No procedure to cure ALGS completely
- **Progressive Familial Intrahepatic Cholestasis (PFIC):** a rare genetic liver disorder in which liver cells don't release bile properly, causing bile accumulation in the cells. Surgical treatment includes external or internal biliary diversions
- Biliary Atresia (BA): a rare disease of the liver and bile ducts that occurs in infants. Currently no cure for BA available. Treatments include liver transplant and Kasai procedure

Source: Frost & Sullivan Analysis. Abbreviations: IBAT, ileal sodium-dependent bile acid transporter






Epidemiology

More ~22,000 targeted patients with ALGS, PFIC, BA in China



Statistically Significant, Clinically Meaningful, and Sustained Improvement in Pruritis



Change from baseline, **** $p \le 0.0001$ (overall population)

- Robust results from the pivotal LUM001-304 study, meeting the efficacy endpoint, improvement in pruritus, and long-term treatment benefit
- The results of the 4 supportive studies support the pivotal study efficacy results and effective dose
 - The effect of maralixibat treatment on all efficacy parameters was maintained after Week 48 up to Week 240.


Safety Data of LIVMARLI in ALGS Includes 5 Years of Follow-up

Events observed over 5% patients	Number of events per 100 person-years
Diarrhea	41.6
Abdominal pain	38.6
Vomiting	19.8
Nausea	2.9
Fat-soluble vitamin deficiency	11.1
Transaminase increased	6.9
GI bleeding	3.8
Bone fractures	3.3

- Population Exposure Status: Maralixibat has been studied in > 1600 subjects, including more than 180 pediatric or adult subjects with cholestatic liver disease. Of 119 children with cholestatic liver disease treated for up to 5 years, 86 had ALGS.
- Common Adverse Events: In the ALGS pool, events of diarrhea and abdominal pain were the most frequently reported AE in subjects exposed to maralizibat and placebo.
- Serious Adverse Events: in the ALGS pooled population, no subjects in the majority of maralizibat clinical studies experienced SAE and no deaths were reported.




Long-term Data Emerging Suggests Improvement in Event-Free Survival and Growth



- Cohort of 84 patients treated with maralixibat compared with an external matched control cohort of 469 patients from the GALA^{*} Database
- Events defined as: liver transplantation; biliary diversion surgery; liver decompensation event; or death.

Maralixibat improves growth in patients with Alagille syndrome: A 4-year analysis Binita M Kamath,¹ Douglas B Mogul,² Marshall Baek,² Tiago Nunes,³ Pamela Vig² ¹Division of Gastraenterology A Nuttien, Hospital for Sick Children and University of Toomb, ON, Canada.

- · Patients with ALGS typically suffer significant growth deficiency
- Mean height Z-score significantly increased from Baseline to Week 204 in ALGS patients treated with maralixibat




*p=0.0004. CFB, change from baseline.



Commercial Launch of LIVMARLI in Reimbursed Market in Jan 2024

China market potential: \$100-150 million in ALGS and \$200-250 million for three indications combined



Anticipated approval and launch in Taiwan and Hong Kong between 2H 2023 and 1Q 2024







Hunterase: The First and the Only Approved Enzyme Replacement Therapy for MPS II in China



Hunterase[®] – Early Commercialization In Non-reimbursed Market

Identification of new patients accelerates, and commercial insurance coverage expands





MPS II is a rare, disabling and lifethreatening genetic disease



In East Asian countries, MPS II is the most common form of MPS disorders



Chinese government has included MPS II on the "**National Rare Disease List**" as a disease group to target



Life expectancy of patients with severe MPS II (60%-80% of cases) is significantly reduced



Death occurs generally before the age of 25

Hunterase Commercial Updates





Total 739 identified patients

- 72 patients newly identified in 2023
- 263 patients newly identified in 2022
- **195** identified in 2021 since launch in May 2021
- 209 registered by patient group



Hunterase has entered into 109 cities' commercial insurance program ("Huiminbao") as of end of June 2023, covering a populationof 586 million in China

- 72% of Hunterase treated patients are covered by commercial insurance
- Reimbursement rate ranges
 from 20% to 90%





CAN106

Clinically De-risked, Near Commercialization, Targeting Multiple Indications with Significant Market Potential

CAN106 – Long-acting Anti-C5 Therapy for Complement Disorders

Novel, long-acting monoclonal antibody for the treatment of complement-mediated diseases, including PNH, myasthenia gravis (MG) and various other complement-mediated diseases that are targeted by anti-C5 antibodies.

Recent Highlights

Completed first-in-human study conducted in Singapore in 2021 and **positive top-line data** reported

- IND Approval for the treatment of PNH in China in Jul. 2021
- **Orphan Drug Designation granted by FDA** for treatment of myasthenia gravis in Nov. 2022

Positive Phase 1b data in PNH patients reported in Jun. 2023

Disease Overview

Paroxysmal nocturnal hemoglobinuria (PNH)


belongs to a group of fatal and rare disorders that occur when the complement system is dysregulated. In patients with PNH, the proteins that normally protect their red blood cells are not present, leaving these denuded cells susceptible to complement attack, which results in their destruction (hemolysis).

This leads to severe anemia, thromboembolism, gastrointestinal pain and dysfunction, fatigue, cardiac failure, pulmonary hypertension, renal impairment, and eventually, death.

PNH is an acquired genetic condition that can occur at any age across genders and race, but most commonly presents in adults in their 30s to 40s and continues for the life of the patient.

Source: Frost & Sullivan Analysis. Abbreviations: IBAT, ileal sodium-dependent bile acid transporter





Mechanism of Action

CAN106 binds to the α chain of C5, which prevents C5 from being cleaved into C5a and C5b by C5 convertase, thus preventing MAC formation and cell lysis

CAN106 preserves the generation of C3b, which is essential for the clearance of circulating immune complexes and the normal phagocytosis of bacterial and fungal pathogens




C5 linhibition Remains the Current Standard of Care for PNH

Recent studies raise concerns about potential risks associated with proximal inhibitors in anti-complement treatment.

- Enhanced complement inhibition leads to heightened breakthrough hemolysis risk upon inhibition loss, due to increased susceptible PNH clones. .
- Enzymatic activities upstream of the terminal pathway contribute to amplified breakthrough hemolysis risk with proximal inhibition.
- Loss of inhibition at the proximal level triggers exacerbated intra- and extra-vascular hemolysis severity, contrasting with terminal level inhibition loss.

Illustration of Complement Pathways




PNH = Paroxysmal nocturnal hemoglobinuria *Risitano AM, et al. Immunological Review s. 2022 In China for Global



Dose-dependent, Rapid and Substantial Effects on LDH and Hgb

Cohort 3: LDH, a biomarker of hemolysis, was reduced by 81% at Week 13. All subjects showed rapid and sustained LDH reduction, with 88% (7/8) subjects in Cohort 3 achieving LDH < 1.5 x ULN at least once after Week 3



Mean Hgb level (SD) during 54-week treatment

Extension Dose (after Week 26) Cohort Maintenance Dose 1 20 mg/kg q4w40 mg/kg q4w 2 40 mg/kg q4w 3 80 mg/kg q4w 80 mg/kg q4w

In China for Global

Hab levels improved across all cohorts.


- Cohort1: Mean Hgb increase from baseline of 1.8 g/dL at Week 26 and 3.8 g/dL at Week 54.
- Cohort 2: Mean Hgb increase from baseline of 2.0 g/dL at Week 26 and 2.4 g/dL at Week 42.
- Cohort 3: Mean Hgb increase from baseline of 1.0 g/dL at Week 13.
- Two subjects in Cohort 3 at Week 13 achieved Hgb \geq 12 g/dL in the absence of transfusion.

LDH=lactate dehydrogenase. Target range for hemolysis inhibition is LDH is < 1.5 x ULN = 351 U/L; Tw o breakthrough hemolysis events caused by COVID-19 were reported at Week 12 in Cohort 3, leading to transient elevations in LDH (>2x ULN) that recovered by Week 13.



CAN106 – Potential for Other Complement Disorders

Potential "Pipeline in a Product". Initial development efforts focused on PNH treatment. Estimated global market revenue projections of >\$9B in 20251



Abbreviation: PNH, paroxysmal nocturnal hemoglobinuria. Notes: 1. According to Alexion Investor Day 2020 news release published on October 6, 2020. 2, Risitanon and Rotoli, 2008 & Chinese KOL interview; China aHUS Diagnosis and Treatment Consensus, 2017; China MG Diagnosis and Treatment Guideline, 2015 & How ard et cl, 2017; Zanella and Barcellini, 2014 & Berentsen and Sundic, 2015; Mahmoud et cl, 2016; CANbridge research

In China for China

In China for Global In Global for

🖒 CAN bridge

CAN106 – Differentiated Follow-On Indication Strategy

CAN106's multi-indication potential, coupled with the limited access to the current available anti-C5 therapies in most parts of the world, allows for versatile indication expansion and go-to-market strategies to maximize its global commercial value

		Soliris & U	Iltomiris Ap	proval and	Reimburse	ment Status	1	
							- <u>18</u>	
	PNH	~	\checkmark	✓	✓	\checkmark	✓	\checkmark
iris	aHUS	√	✓	✓	✓	√	✓	✓
Soliris	gMG	✓	0	~	0	0	0	✓
	NMOSD	√	0	✓	✓	0	0	✓
	PNH	~	✓	~	✓	✓	~	✓
niris	aHUS	√	✓	✓	✓	✓	✓	✓
Ultomiris	gMG	√	х	0	0	0	0	✓
2	NMOSD	X	X	0	0	0	0	0

Kow	1	Annroved	Raimburgad	\cap	Annroved	Not Reimbursed	Y	Not Approved
ney.	V	Appioveu,	Reinburseu	0	Appioveu,	Not Keimburseu		Not Approved

PNH ~5K ~8K ~1K aHUS ~3K ~2K ~450 gMG ~66K ~102K ~13K NMOSD ~6K ~13K ~4K

Diagnosed Prevalence for Select Complement-mediated Disorders²

- Despite broad approval of existing C5 inhibitors, patient access to Alexion's therapies approved in gMG and NMOSD is still limited, particularly in European and Rest-of-World markets
- · Access to anti-C5 therapies in developing countries is even more limited or non-existent
- Future CAN106 clinical development and commercialization plans can be **optimized to prioritize development in de-risked, high-value complement**mediated disorders in markets underserved by Soliris and Ultomiris
- Additional indications where anti-C5 therapies are not approved yet are available for exploration and expansion

1. ClearView Healthcare Partners Analysis; Japan gMG reimbursement status inferred from previous reimbursement activities 2. CANbridge Internal Analysis



CAN106 – Complement Advisory Board

Board will offer guidance on the CAN106 global development program, as well as explore the potential for CAN106 in other indications



Anthony Amato, MD

- Brigham and Women's Hospital Distinguished Chair in Neurology
- Chief of the Neuromuscular Division and Director of the Clinical Neurophysiology Laboratory at Brigham and Women's Hospital
- Professor of Neurology at Harvard Medical School



Gerald Cox, MD, PhD

- Chief Development Strategist & Interim Chief Medical Officer
- Clinical geneticist and pediatrician at Boston Children's Hospital
- Former Chief Medical
 Officer at Editas
 Medicine
- Vice President, Rare Disease Clinical Development at Sanofi



Jean Francis, MD

- Medical Director of Kidney Transplant Program at Boston Medical Center and Boston Univ Sch of Med
- Medical Director of Combined Pancreas Transplant Program at Boston Medical Center and Brigham and Brigham & Women's Hospital
- Associate Professor of Medicine at Boston Univ Sch of Med



Richard Polisson, MD, MHSc

- Clinical Development Consultant
- Former CMO at Artax Biopharma
- Senior VP and Head of Transl Med at Sanofi-Genzyme R&D Center
- Clin Dir of Arthritis Unit and Chair of Mallinckrodt Clin Res Unit Scientific Adv Comm at Massachusetts General Hospital
- Associate Professor of Medicine at Harvard Medical School



Sushrut Waikar, MD, MPH

- Chief of Nephrology at Boston Medical Center
- Norman G. Levinsky Professor of Medicine at Boston University School of Medicine
- Former Constantine L. Hampers, MD Distinguished Chair in Renal Medicine at Brigham and Women's Hospital



Brian Weinshenker, MD

- Professor of Neurology at University of Virginia
- Former Professor of Neurology at Mayo Clinic

Neuromuscular Disorders Rare Disease Drug Development Organ Transplant, PNH, Thrombotic Microangiopathy

Rare Disease Drug Development, Rheumatologic Diseases Renal Diseases, Noninvasive Biomarkers of Renal Injury and Fibrosis NMOSD and Other CNS Demyelinating Diseases







CAN008:

Development in Newly Diagnosed GBM

CAN008 – CD95-Fc Fusion Protein for Glioblastoma Multiforme (GBM)

CAN008

CD95L

Tumor Cell Growth / Migration

CAN008 is in clinical development as a first-line therapy for GBM in China

Recent Highlights

- An independent data monitoring committee completed an interim analysis and review of the ongoing Phase 2 study of CAN008 and recommended the study continue without any changes to the current trial design in July 2023.
- Currently in Phase 2 registrational trial in newly diagnosed GBM in China. Patient enrollment (N = 117) completed in March 2023
- Long-term data from phase 1/2 trial presented in ESMO in Mar 2023 shows
 - 67% five-year OS rate compared to 8.2% in institutional database
 - 83% OS at two years vs. 34.3% OS from institutional database
 - 17.95 months median PFS vs. 5.8 months PFS in historical group

GBM Overview

- A rare oncologic disease with lower incidence than other cancer types
- Median age of diagnosis is 64 years, and it is slightly more common (1.59 times) in men as compared to women
- The **most common and malignant** type of glioma in adults. About 45% of gliomas are glioblastoma multiforme
- Estimated 5-year survival of 5.5% globally and below 5% in China
- Treatment options: surgical resection, adjuvant chemotherapy with TMZ, tumor treating field (TTF), bevacizumab (Avastin)


Mechanism of Action

CD95L binds to its receptor, CD95, on the cell surface and induces the oligomerization of CD95, which triggers an intracellular signaling cascade that stimulates tumor cell growth and migration

CAN008 acts as a soluble receptor that specifically binds to CD95L and blocks the endogenous CD95 / CD95L signaling pathway in tumor cells. CAN008 also blocks CD95 / CD95L engagement on T cells, which prevents T cell apoptosis and restores immune function

As the oligomerization of CD95 is blocked and signal transduction is inhibited, the growth and migration of tumor cells are suppressed


Epidemiology





CAN008 – Ongoing Phase 2 Registrational Trial in Newly Diagnosed GBM

Phase 2 Multi-center, randomized, double-blind, placebo-controlled study



Primary endpoint

• Progression-free survival (PFS)

Interim Readout

Progression of 37 cases




Next-gen Gene Therapy Pipeline



Proprietary Gene Therapy Technology Platform & Powerful Discovery Engine

We continue to invest in gene therapy as our next-generation technology development and expand our in-house R&D activity to generate promising leads for treatment of rare diseases

Research Collaborations with World-Renowned Investigators and Academic Institutions



Potentially best-in-class SMAGT (Global rights secured)

Novel tissue-tropic AAV capsid discovery

Potentially best-in-class DMD GT

In-House AAV Gene Therapy Platform and Process Development Facility



Platform technology with guided AAV tissue targeting, such as CNS or muscles



AAV process development lab and pilot plants in Greater Boston

Strategic Collaborations with Innovative Industry Partners



Licensed worldwide rights to **liver-tropic capsid** for AAV gene therapy products to treat Fabry and Pompe diseases

Exclusive worldwide rights to **proprietary RNA Assembly Technology** to develop next-gen GT for dystrophinopathies



CAN203 – Second Generation Gene Therapy for Spinal Muscular Atrophy

SMA Pathophysiology Illustration Spinal Muscular Atrophy (SMA) Mutation in . the SMN1 gene ٠ Loss of motor neurons in the anterior horns of the spinal cord prevents signalling Deficiency in between the brain the SMN protein and skeletal muscles leads to splicing **Progressive muscle** defects in motor neurons weakness and atrophy

CAN203

- Second-gen gene therapy to potentially treat SMA type 1-3 (from infants to adult patients)
- Endogenous promoter: regulated, targeted tissue expression to avoid unwanted toxicity in liver and heart
- Codon optimized: enhanced tissue expression
- May achieve safer, more cost-effective treatment with lower doses compared to standard of care gene therapy
- Presented additional preclinical data at the premier academic conference 2022 and 2023 ASGCT.

Epidemiology

- Autosomal recessive genetic inheritance
- 1 in 6,000 to 1in 10,000 children born with SMA
- Affects all racial and ethnic groups
- One of the most common rare diseases

Patients with SMA over the age of two cannot be treated with the 1st-gen gene therapy Zolgensma[®]

Unmet Need


- Black box warning of serious liver injury associated with Zolgensma[®]
- · Limited access due to high price

Source: Cow en Equity Research and SMA Foundation.



CAN203 - Preclinical Data Presented at 2022 and 2023 ASGCT

Head-to-head comparison between the 2nd-generation vector (CAN203) and the reference vector (designed similar to Zolgensma[®]): both IV* and ICV* injections demonstrate therapeutic advantages



In vivo data demonstrates the superiority of the 2nd-generation vector in extending lifespan, improving motor function, and eliminating liver toxicity (data not shown)

🖒 CAN bridge

31


IV: Intravenous; ICV: Intracerebroventriculai

In China for China



CANbridge Innovative AAV Capsid Platform: BEST²AAV

Addressing limitations of current AAV technology



Note: Tabebordbar M et al, Cell 2021



Comparison of CANbridge BEST² with Other Novel Capsid Approaches

Natural Cap Discovery

100s identified

Pros

Cons

- Nature made from evolution
- Serendipitous
- Broad tissue tropism
- NAb/CTLs
- Unknown species translatability

Rational Design


- Based on understanding of receptor biology
- More predictable species
 translatability
- May alter NAb
- Lack of full understanding of receptor biology
- Hard to engineer into AAV

Directed Evolution

- High throughput
- Inclusive of all possible combinations nature can't do
- Time consuming on panning
 Unknown species translatability
- Costly validation on transability
 and manufacturability
- Different tissues may need different AAVs

In-Silico Design

- As for Directed evolution
- Powerful AI learning capsid biology to guide rational library design
- As for Directed evolution
- Different tissues may need different AAVs



CANbridge AAV-BEST²


- Small edits to avoid impact on CMC developability
- Liver de-targeted AAV to avoid peripheral sinkers
- One AAV fits all, only need to replace the "GOI"
- Simplify manufacturing process development with one AAV
- Programmable "GPS-like" for a specific tissue or tissues
 - Single or multi-tissue delivery capability
- Bypass NAb \rightarrow increases the number of patients eligible to AAV gene therapy
- Two targets on the same tissue can be used by two different BEST² to further avoid NAbs for repeated dosing





Financial Review

1H 2023 Financial Highlights









CANBRIDGE-B 01228. HK

www.canbridgepharma.com





THANK YOU



CANBRIDGE-B 01228. HK

www.canbridgepharma.com

